DOPAMINE HYDROCHLORIDE Drug Patent Profile
✉ Email this page to a colleague
When do Dopamine Hydrochloride patents expire, and when can generic versions of Dopamine Hydrochloride launch?
Dopamine Hydrochloride is a drug marketed by Abbott, Abraxis Pharm, Am Regent, Baxter Hlthcare, Hikma Intl Pharms, Hospira, Igi Labs Inc, Intl Medication, Lyphomed, Smith And Nephew, Teligent, Teva Parenteral, Warner Chilcott, and B Braun. and is included in thirty-six NDAs.
The generic ingredient in DOPAMINE HYDROCHLORIDE is dopamine hydrochloride. There are nine drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the dopamine hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Dopamine Hydrochloride
A generic version of DOPAMINE HYDROCHLORIDE was approved as dopamine hydrochloride by HOSPIRA on February 4th, 1982.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for DOPAMINE HYDROCHLORIDE?
- What are the global sales for DOPAMINE HYDROCHLORIDE?
- What is Average Wholesale Price for DOPAMINE HYDROCHLORIDE?
Summary for DOPAMINE HYDROCHLORIDE
US Patents: | 0 |
Applicants: | 14 |
NDAs: | 36 |
Finished Product Suppliers / Packagers: | 6 |
Raw Ingredient (Bulk) Api Vendors: | 108 |
Clinical Trials: | 1,011 |
Patent Applications: | 2,049 |
What excipients (inactive ingredients) are in DOPAMINE HYDROCHLORIDE? | DOPAMINE HYDROCHLORIDE excipients list |
DailyMed Link: | DOPAMINE HYDROCHLORIDE at DailyMed |
Recent Clinical Trials for DOPAMINE HYDROCHLORIDE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Neurocrine Biosciences | Phase 4 |
Stephen Ruedrich | Phase 4 |
University of Nebraska | Phase 1 |
Pharmacology for DOPAMINE HYDROCHLORIDE
Drug Class | Catecholamine |